初治HIV-1感染者中fostemsavir耐药相关gp120位点的替换分析
该研究回顾性分析409例新诊断HIV-1感染者的gp120序列,评估与fostemsavir耐药相关的L116P、A204D、S375H/M/T、M426L、M434I和M475I突变频率。结果显示总体突变频率较低,以S375T最常见(13.2%),且不同亚型和嗜性间存在位点差异。
要点
- 初治HIV-1感染者中fostemsavir耐药相关gp120突变总体频率低。
- S375T是最常见替换(13.2%),其降低fostemsavir疗效的作用较小。
- 位点375和426的突变频率在R5/非R5及B/非B亚型间存在显著差异。
核心结论
- 初治HIV-1感染者中fostemsavir耐药相关gp120替换在不同亚型及R5/非R5变异体中均可检出,但总体频率低,以S375T为主。
研究设计与样本
- 回顾性分析409例新诊断HIV-1感染者的gp120序列,评估特定耐药相关位点突变并按HIV亚型和嗜性分组。
主要发现
- 突变频率为S375T 13.2%、M426L 6.8%、M434I 2.9%、M475I 2.7%、S375H 1.0%/M 0.8%、L116P 0.31%。
- 位点375在R5与非R5株及B与非B亚型间差异显著,主要由S375T驱动。
- 位点426在B与非B亚型间差异显著,由罕见替换尤其是M426R驱动(P < 0.00001)。
- env恒定区的变异性在非B病毒群体中似乎更为突出。
临床怎么用
- 初治HIV-1感染者中fostemsavir耐药相关突变总体少见,S375T虽常见但降低疗效作用较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Fostemsavir, a novel attachment inhibitor targeting the HIV-1 gp120, has demonstrated wide in vitro activity. However, the high rate of HIV gp120 substitutions could jeopardize its efficacy. We investigated envelope (env) substitutions at positions associated with resistance to fostemsavir in patients with a new HIV-1 diagnosis according to HIV subtype and tropism. METHODS: Gp120 sequences from 409 subjects were retrospectively analysed and the presence of the L116P, A204D, S375H/M/T, M426L, M434I and M475I mutations was evaluated. Other amino acid changes at the same positions were also recorded. The variability at each amino acid position was evaluated using Shannon entropy. RESULTS: The frequency of mutations was: S375T (13.2%); M426L (6.8%); M434I (2.9%); M475I (2.7%); S375H (1.0%)/M (0.8%) and L116P (0.31%). Statistically significant differences were found at positions 375 (R5/non-R5 strains and B/non-B subtypes) and 426 (B/non-B subtypes); post hoc analysis revealed that significance for position 375 was steered by S375T while for position 426 significance was governed by unusual substitutions, in particular M426R (B/non-B, P < 0.00001). The variability of env constant domains appeared to be more relevant in the non-B virus population. CONCLUSIONS: In conclusion, gp120 substitutions were detected in different subtypes and in both R5 and non-R5 variants. Despite the great variability of gp120, the frequency of mutations was low overall and the predominant substitution was S375T, the role of which in reducing fostemsavir efficacy is less substantial.
引用
- Lepore L, Fabrizio C, Bavaro DF, et al. Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naive HIV-1-positive individuals. J Antimicrob Chemother. 2020. PMID: 32191306. doi:10.1093/jac/dkaa034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。